Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linifanib versus sorafenib in advanced hepatocellular carcinoma
NL-OMON34685Phase 3Active, not recruiting
- Sponsor
- Abbott Laboratories
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Linifanib with Sorafenib (2 arms). Primary endpoint: Overall survival. Started May 2010; status: active, not recruiting.
02
Drugs
linifanibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON34685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34685.